Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of the safety, tolerability, efficacy and immunological responses of the interleukin-2 analogue Aldesleukin (Proleukin) in the treatment of systemic lupus erythematosus as prototypic autoimmune disease.

Next Previous
X
Search
Trial Profile

Evaluation of the safety, tolerability, efficacy and immunological responses of the interleukin-2 analogue Aldesleukin (Proleukin) in the treatment of systemic lupus erythematosus as prototypic autoimmune disease.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aldesleukin (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions; Biomarker; Pharmacodynamics
  • Acronyms PRO-IMMUN

    • Most Recent Events

    • 16 Nov 2016 Primary endpoint (Immunological response rate) has been met, according to results presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 16 Nov 2016 Results analysing presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 09 May 2015 Planned number of patients changed from 10 to 12 as reported by EU Clinical Trials Register record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top